DK3019176T3 - Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf - Google Patents

Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf Download PDF

Info

Publication number
DK3019176T3
DK3019176T3 DK13889025.6T DK13889025T DK3019176T3 DK 3019176 T3 DK3019176 T3 DK 3019176T3 DK 13889025 T DK13889025 T DK 13889025T DK 3019176 T3 DK3019176 T3 DK 3019176T3
Authority
DK
Denmark
Prior art keywords
procedures
preparing
application
inflammatory compositions
acellular pro
Prior art date
Application number
DK13889025.6T
Other languages
English (en)
Inventor
Mark D Scott
Wendy M Toyofuku
Duncheng Wang
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2013/050546 external-priority patent/WO2014008611A1/en
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of DK3019176T3 publication Critical patent/DK3019176T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1178—Spleen cells
DK13889025.6T 2013-07-12 2013-12-13 Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf DK3019176T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CA2013/050546 WO2014008611A1 (en) 2012-07-12 2013-07-12 Method for inducing immune stimulation using non-proliferative allogeneic leukocytes
PCT/CA2013/050543 WO2014008608A1 (en) 2012-07-12 2013-07-12 Acellular pro-tolerogenic compositions and process for making same
PCT/CA2013/050963 WO2015003240A1 (en) 2013-07-12 2013-12-13 Acellular pro-inflammatory compositions, process for making same and methods of using same

Publications (1)

Publication Number Publication Date
DK3019176T3 true DK3019176T3 (da) 2020-06-22

Family

ID=52279371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13889025.6T DK3019176T3 (da) 2013-07-12 2013-12-13 Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf

Country Status (4)

Country Link
US (1) US11007221B2 (da)
EP (1) EP3019176B1 (da)
DK (1) DK3019176T3 (da)
WO (1) WO2015003240A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf
US10561685B2 (en) 2014-07-10 2020-02-18 Canadian Bllood Services Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US5908624A (en) 1996-06-27 1999-06-01 Albany Medical College Antigenic modulation of cells
WO1997028254A1 (en) 1996-02-01 1997-08-07 Biomedical Frontiers, Inc. Antigenic modulation of cells
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
PT972519E (pt) 1997-03-07 2006-12-29 Jimro Co Ltd Indutores de imunotolerância
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20070009497A1 (en) 2004-03-10 2007-01-11 Steinman Ralph M Dendritic cell expanded T suppressor cells and methods of use thereof
CA2581063C (en) 2004-09-15 2016-03-22 The Trustees Of The University Of Pennsylvania Methods for the isolation and expansion of cord blood derived t regulatory cells
WO2007120128A1 (en) 2006-04-13 2007-10-25 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection
US8067151B2 (en) 2007-02-09 2011-11-29 Canadian Blood Services Cold storage of pegylated platelets at about or below 0° C.
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2416789B1 (en) 2009-04-07 2017-06-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US9211321B2 (en) * 2009-10-27 2015-12-15 Immunicum Ab Method for proliferation of antigen-specific T cells
EP2638159B1 (en) 2010-11-11 2019-04-24 University of Miami Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
AU2012304313A1 (en) 2011-09-08 2014-03-06 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf

Also Published As

Publication number Publication date
US11007221B2 (en) 2021-05-18
EP3019176B1 (en) 2020-05-06
WO2015003240A1 (en) 2015-01-15
EP3019176A4 (en) 2017-03-15
EP3019176A1 (en) 2016-05-18
US20160206655A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3035955T3 (da) Sammensætning og vaccine til behandling af lungekræft
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK2970872T3 (da) Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider
DK3219707T3 (da) Fremgangsmåde til fremstilling af substituerede oxiraner og triazoler
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3702443T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller
DK2968673T3 (da) Fremgangsmåde til decellularisering af vævstransplantater
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3025586T3 (da) Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf
DK3685848T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3102184T3 (da) Stabile formuleringer af peptider og fremgangsmåder til fremstilling